LEVEL 4 A10BB01

Δραστικές

Φάρμακα

  • DRUGBANK - Glibenclamide
  • indication:

    Indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.

  • pharmacology:

  • mechanism:

    Sulfonylureas such as glibenclamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.

  • toxicity:

    Oral rat LD<sub>50</sub>: > 20,000 mg/kg. Oral mouse LD<sub>50</sub>: 3250 mg/kg.

  • absorprion:

    Significant absorption within 1 hour and peak plasma levels are reached within 4 hours.

  • halflife:

    10 hours

  • roouteelimination:

    Glyburide is excreted as metabolites in the bile and urine, approximately 50% by each route. This dual excretory pathway is qualitatively different from that of other sulfonylureas, which are excreted primarily in the urine.

  • volumedistribution:

  • clearance: